COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Longevity of Multi-Slitted Catheter With Lantern Technology (Lantern)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03819634
Recruitment Status : Completed
First Posted : January 28, 2019
Last Update Posted : September 20, 2019
ConvaTec Inc.
Information provided by (Responsible Party):
Bruce A. Buckingham, Stanford University

Brief Summary:
To determine time to set failure when the Convatec Inset II with Lantern technology (Convatec Lantern) infusion set with multi-slitted catheter is worn for up to 10 days

Condition or disease Intervention/treatment Phase
Insulin Dependent Diabetes Mellitus 1 Device: Inset II with Lantern Technology Not Applicable

Detailed Description:

This is a pilot study to obtain preliminary data to determine the time to set failure when the Lantern infusion set is worn for up to 10 days. The study is not intended for registration purposes or to support a 510(k) submission. The study will be conducted at one site: Stanford University.

This study will enroll 24 subjects (as per FDA approval) to establish the maximum length of Lantern infusion set wear when 80% of sets are still functional (excluding accidental "pull-outs"). Each participant will place the set and wear it for 10 days or until set failure and data will be collected on the cause of set failure. If a set is accidentally pulled out, it can be replaced by the subject. Failures are based on:

  1. Presence of serum ketones with hyperglycemia
  2. Unexplained hyperglycemia
  3. Signs of infection at the infusion site
  4. Pump occlusion alarm
  5. Adhesive failure

Since infusion set failures will occur after variable lengths of wear, regularly scheduled visits are unlikely to capture the day of an infusion set failure. Instead the subject will be taught how to insert the set, measure erythema and induration with a ruler marked in millimeters and to take a picture of the infusion site. Subjects will be instructed to text the study team when they remove their infusion set and to send a picture of the infusion site and measurements. If there is any evidence of an infection (≥10 mm of erythema or induration), they will be asked to come in that day for an unscheduled visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: To determine length of infusion set wear for up to a maximum of 10 days
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Longevity of Multi-Slitted Catheter, the Convatec Inset II With Lantern Technology
Actual Study Start Date : January 25, 2019
Actual Primary Completion Date : April 20, 2019
Actual Study Completion Date : April 20, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Lantern infusion set
Multi-slitted lantern infusion set
Device: Inset II with Lantern Technology
Each participant will insert the Inset II with Lantern technology and wear it for 10 days or until set failure and data will be collected on the cause of set failure. The infusion set will be used with their usual insulin pump.

Primary Outcome Measures :
  1. Time to infusion set failure [ Time Frame: 10 days of infusion set wear ]
    Time to when the infusion set fails and needs to be replaced for:

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Type 1 Diabetes by clinical definition

  1. Age 22 and over
  2. On tethered insulin pump therapy for at least 3 months using Lispro or Aspart insulin.
  3. Hemoglobin A1c level less than or equal to 9%
  4. Eating more than 60 grams of carbohydrate each day
  5. For females, not currently known to be pregnant
  6. Understanding and willingness to follow the protocol and sign informed consent
  7. Willingness to wear the experimental infusion sets
  8. Willingness to have photographs taken of their infusion sites
  9. Ability to speak, read and write in the language of the investigators

Exclusion Criteria:

The presence of any of the following is an exclusion for the study:

  1. Diabetic ketoacidosis in the past 3 months
  2. Severe hypoglycemia resulting in seizure or loss of consciousness within 3 months prior to enrollment
  3. Pregnant or lactating
  4. Known tape allergies
  5. Active infection
  6. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol
  7. Known cardiovascular events in the last 6 months
  8. Known acute proliferative diabetic retinopathy
  9. Known adrenal disorder
  10. Current treatment for a seizure disorder
  11. Inpatient psychiatric treatment in the past 6 months
  12. Lack of stability on medication 1 month prior to enrollment including antihypertensive, thyroid, anti-depressant or lipid lowering medication.
  13. Use of SGLT inhibitor
  14. Suspected drug or alcohol abuse
  15. Dialysis or end stage kidney disease

Note: Adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03819634

Layout table for location information
United States, California
Palo Alto, California, United States, 94305
Sponsors and Collaborators
Stanford University
ConvaTec Inc.
Layout table for investigator information
Principal Investigator: Bruce A Buckingham, MD Stanford University
Layout table for additonal information
Responsible Party: Bruce A. Buckingham, Professor of Pediatric Endocrinology, Stanford University Identifier: NCT03819634    
Other Study ID Numbers: IRB #45812
First Posted: January 28, 2019    Key Record Dates
Last Update Posted: September 20, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases